Integra LifeSciences (NASDAQ:IART) Stock Breaks Above Two Hundred Day Moving Average – Here’s Why

Integra LifeSciences Holdings Corporation (NASDAQ:IART) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $14.10 and traded as high as $15.15. Integra LifeSciences shares last traded at $14.82, with a volume of 1,174,234 shares trading hands.

Analysts Set New Price Targets

IART has been the topic of a number of research analyst reports. Weiss Ratings upgraded Integra LifeSciences from a “sell (e+)” rating to a “sell (d+)” rating in a report on Monday, October 26th. Zacks Research downgraded Integra LifeSciences from a “hold” rating to a “strong sell” rating in a report on Monday, October 26th. Truist Financial set a $13.00 price objective on Integra LifeSciences and gave the stock a “hold” rating in a report on Friday, October 23rd. Citigroup reaffirmed an “outperform” rating on shares of Integra LifeSciences in a research note on Thursday, October 22nd. Finally, BMO Capital Markets reiterated a “market perform” rating and set a $14.00 target price (down from $15.00) on shares of Integra LifeSciences in a report on Thursday, October 22nd. Two investment analysts have rated the stock with a Buy rating, five have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $16.12.

Integra LifeSciences Stock Performance

The firm has a market cap of $1.15 billion, a price-to-earnings ratio of 87.18, a PEG ratio of 0.53 and a beta of 1.28. The stock’s fifty day moving average is $14.67 and its two-hundred day moving average is $14.10. The company has a debt-to-equity ratio of 1.67, a quick ratio of 2.21 and a current ratio of 3.62.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.03. Integra LifeSciences had a net margin of 0.79% and a return on equity of 18.63%. The company had revenue of $411.18 million during the quarter, compared to analyst estimates of $413.16 million. During the same quarter last year, the firm posted ($0.07) EPS. On average, analysts expect that Integra LifeSciences Holdings Corporation will post 2.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Large investors have recently added to or reduced their stakes in the stock. Paradigm Capital Management Inc. NY acquired a new position in Integra LifeSciences during the 2nd quarter valued at $61,766,000. Access Investment Management LLC raised its stake in shares of Integra LifeSciences by 39.5% in the third quarter. Access Investment Management LLC now owns 564,982 shares of the life sciences company’s stock worth $9,198,000 after acquiring an additional 159,980 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in shares of Integra LifeSciences in the 4th quarter valued at $879,000. Bank of New York Mellon Corp acquired a new position in shares of Integra LifeSciences during the second quarter valued at $8,723,000. Finally, Louisiana State Employees Retirement System acquired a new stake in Integra LifeSciences in the first quarter worth about $280,000. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.